HAROLD SHINE to Genetic Vectors
This is a "connection" page, showing publications HAROLD SHINE has written about Genetic Vectors.
Connection Strength
0.725
-
Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers neuroprotection that exceeds the transduced population. J Neurosci. 1997 Sep 01; 17(17):6504-11.
Score: 0.109
-
Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat). Gene Ther. 1997 Apr; 4(4):275-9.
Score: 0.106
-
Immune activation is required for NT-3-induced axonal plasticity in chronic spinal cord injury. Exp Neurol. 2008 Feb; 209(2):497-509.
Score: 0.056
-
Expression of neurotrophin-3 promotes axonal plasticity in the acute but not chronic injured spinal cord. J Neurotrauma. 2006 Aug; 23(8):1254-60.
Score: 0.051
-
Semi-automated quantification of axonal densities in labeled CNS tissue. J Neurosci Methods. 2006 Sep 15; 155(2):172-9.
Score: 0.049
-
In situ expression of brain-derived neurotrophic factor or neurotrophin-3 promotes sprouting of cortical serotonergic axons following a neurotoxic lesion. J Neurosci Res. 2005 Nov 01; 82(3):404-12.
Score: 0.048
-
Neurotrophic factors expressed in both cortex and spinal cord induce axonal plasticity after spinal cord injury. J Neurosci Res. 2003 Oct 15; 74(2):221-6.
Score: 0.042
-
Neurotrophin-3 expressed in situ induces axonal plasticity in the adult injured spinal cord. J Neurosci. 2003 Feb 15; 23(4):1424-31.
Score: 0.040
-
Improvement of spatial learning and memory after adenovirus-mediated transfer of the nerve growth factor gene to aged rat brain. Hum Gene Ther. 2002 Dec 10; 13(18):2173-84.
Score: 0.039
-
Permanent rescue of lesioned neonatal motoneurons and enhanced axonal regeneration by adenovirus-mediated expression of glial cell-line-derived neurotrophic factor. J Neurosci Res. 1998 Dec 15; 54(6):766-77.
Score: 0.030
-
Neuroprotection of spinal motoneurons following targeted transduction with an adenoviral vector carrying the gene for glial cell line-derived neurotrophic factor. Exp Neurol. 1998 Sep; 153(1):102-12.
Score: 0.029
-
Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies. Hum Gene Ther. 1996 Jun 20; 7(10):1241-50.
Score: 0.025
-
Delayed intramuscular human neurotrophin-3 improves recovery in adult and elderly rats after stroke. Brain. 2016 Jan; 139(Pt 1):259-75.
Score: 0.024
-
Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain. Hum Gene Ther. 1995 Oct; 6(10):1317-22.
Score: 0.024
-
Adenovirus-mediated gene therapy for experimental spinal cord tumors: tumoricidal efficacy and functional outcome. Brain Res. 1995 Sep 11; 691(1-2):76-82.
Score: 0.024
-
Glial cell-derived neurotrophic factor gene delivery enhances survival of human corneal epithelium in culture and the overexpression of GDNF in bioengineered constructs. Exp Eye Res. 2008 Dec; 87(6):580-6.
Score: 0.015
-
Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther. 2000 Feb; 1(2):195-203.
Score: 0.008
-
Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A. 1994 Apr 12; 91(8):3054-7.
Score: 0.005